Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SEFA 1024

Next Previous
Drug Profile

SEFA 1024

Alternative Names: 1024; NST-1024; SEFA-1024

Latest Information Update: 09 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pronova BioPharma
  • Developer NorthSea Therapeutics
  • Class Antihyperlipidaemics; Omega 3 fatty acids; Unsaturated fatty acids
  • Mechanism of Action Cholesterol ester transfer protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hypertriglyceridaemia

Most Recent Events

  • 11 Apr 2025 NorthSea Therapeutics completes a phase II trial in Hypertriglyceridaemia in the US (PO) (NCT05889156)
  • 18 Mar 2024 SEFA 1024 is still in phase I trial for Hypertriglyceridemia in United Kingdom (NorthSea Therapeutics pipeline, March 2024)
  • 28 Nov 2023 No recent reports of development identified for phase-I development in Hypertriglyceridaemia(In volunteers) in United Kingdom (PO, Capsule)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top